Synta Pharmaceuticals Corp.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 2000-01-01

Employees: 51

Market Cap: -

Website: http://www.syntapharma.com

Clinical Trials

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

Phase 3

Terminated

Conditions: Non-Small-Cell Lung Adenocarcinoma
Non-small Cell Lung Cancer Stage IIIB
Non-small Cell Lung Cancer Stage IV
Non-small Cell Lung Cancer Metastatic

Interventions: Drug: Docetaxel
Drug: Ganetespib

First Posted Date: 2013-02-25

Last Posted Date: 2016-07-01

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 696

Registration Number: NCT01798485

Locations: 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 200 locations

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer
HER-2 Positive Breast Cancer
ER/Progressive Response (PR) + Refractory to Prior Hormonal Treatment
Triple Negative Breast Cancer

Interventions: Drug: ganetespib

First Posted Date: 2012-09-03

Last Posted Date: 2015-11-05

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 51

Registration Number: NCT01677455

Locations: 🇬🇧
Synta Pharmaceuticals Investigative Site, Oxford, United Kingdom
🇬🇧
Synta Pharmaceutical Investigative Site, Peterborough, United Kingdom
🇰🇷
Synta Pharmacuetical Investigative Site, Seoul, Seodaemun-GU, Korea, Republic of

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Ganetespib

First Posted Date: 2012-03-23

Last Posted Date: 2015-05-20

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 12

Registration Number: NCT01562015

Locations: 🇨🇦
Synta Pharmaceuticals Investigative Site, Toronto, Ontario, Canada

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer Stage IIIB
Non-small Cell Lung Cancer Stage IV
Non-small Cell Lung Cancer Metastatic

Interventions: Drug: Combination of ganetespib and docetaxel
Drug: Docetaxel

First Posted Date: 2011-05-05

Last Posted Date: 2015-11-05

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 385

Registration Number: NCT01348126

Locations: 🇬🇧
Synta Pharmaceuticals Investigative Site, London, United Kingdom
🇬🇧
Synta Pharmaceuticals Investigational Site, Sutton, United Kingdom
🇺🇸
Synta Pharmaceutials Investigative Site, Boston, Massachusetts, United States

and more 1 locations

Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Elesclomol Sodium

First Posted Date: 2011-01-21

Last Posted Date: 2014-02-03

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 36

Registration Number: NCT01280786

Locations: 🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor Malignancies

Interventions: Drug: STA-9090 (ganetespib) with Docetaxel

First Posted Date: 2010-08-17

Last Posted Date: 2014-09-19

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 27

Registration Number: NCT01183364

Locations: 🇺🇸
Emory University School of Medicine, Atlanta, Georgia, United States

A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST)

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor

Interventions: Drug: Ganetespib

First Posted Date: 2009-12-25

Last Posted Date: 2016-03-10

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 27

Registration Number: NCT01039519

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Oregon Health and Science University-Knight Cancer Institute, Portland, Oregon, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States

and more 1 locations

A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: STA 9090

First Posted Date: 2009-12-14

Last Posted Date: 2014-09-19

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 113

Registration Number: NCT01031225

Locations: 🇺🇸
Arizona Cancer Center; University of Arizona, Tucson, Arizona, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
UCLA Health System, Santa Monica, California, United States

and more 18 locations

A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia

Phase 1

Completed

Conditions: CML
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
AML
ALL
Blast-phase Chronic Myelogenous Leukemia

Interventions: Drug: STA-9090 (ganetespib)

First Posted Date: 2009-08-25

Last Posted Date: 2014-09-18

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 29

Registration Number: NCT00964873

STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Phase 1

Completed

Conditions: AML
MDS
Myeloproliferative Disorders
CML

Interventions: Drug: STA-9090 (ganetespib)

First Posted Date: 2009-03-10

Last Posted Date: 2014-09-18

Lead Sponsor: Synta Pharmaceuticals Corp.

Target Recruit Count: 31

Registration Number: NCT00858572

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy